All News
Are You a High or Low Glucocorticoid Prescriber?
A recent analysis shows thta glucocorticoids (GCs), usually recommended for short-term use in rheumatoid arthritis (RA), are variably used by rheumatologists, and that provider preference is a strong predictors of long-term glucocorticoid use.
Read Article
RheumNow Podcast – Quackademia (10.15.2021)
Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on RheumNow.com.
Read Article
EULAR has updated its recommendations (points to consider - PtC) for rheumatologists managing patients during COVID-19; now with 2 overarching principles and 12 PtC.
Read more on #RheumNow
https://t.co/Q422Sl5Csj
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Risk of anterior uveitis w/ secukinumab is equal to etanercept; but both inferior to mAb TNFi (infliximab, adalimumab) ~ 5000 Rx starts, AU risk/100PY = SEC 6.8; ETA 7.5; INFLIX 2.9; ADA 4. SEC has a 2.3 fold greater risk than ADA/INFX https://t.co/DB9G2mz4mN https://t.co/91FbwCYsmj
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast titled Quackademia available for download.
https://t.co/Y6Pqko1tYm https://t.co/2IvMIfPBkr
Links:
Dr. John Cush RheumNow ( View Tweet)
Fluorosis presenting as lower back pain and stiffness of the neck, shoulders, hips, yellowish-brown tooth discoloration, LOM of Cx spine, hips, shoulders. Pelvic Xrays showed osteosclerosis without sacroiliitis. T scores were +12.1 LS spine, alk phos =479 https://t.co/t2lmoudUIM https://t.co/1pnXJkoCOn
Links:
Dr. John Cush RheumNow ( View Tweet)
In case you missed it…
Still’s Disease Following COVID-19 Vaccination
Read more on #RheumNow
https://t.co/23R41Pydve https://t.co/a44cYIkc98
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Hepatitis B Reactivation with Rituximab and Abatacept
A serologic study of rheumatoid arthritis patients shows that HBV reactivation is seen with rituximab, and less so with abatacept, especially in patients without HBsAb positivity.
https://t.co/l1qCrWCyZd
#RheumNow https://t.co/EUoWt9xGdB
Links:
Dr. John Cush RheumNow ( View Tweet)
In case you missed it:
FDA Approves Avacopan for ANCA-Associated Vasculitis
https://t.co/L7UwhYBaVY
#RheumNow https://t.co/HypjLMLwjU
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
Triple DMARD Rx - MSH vs MLH (Lef). 136 active #RA pts given OL MTX/SSZ/HCQ vs MTX/HCQ/LEF. Equal efficacy (EULAR-Good) was seen at wk 12 (54% vs 59%) and wk 24 (65% vs 62%) - hence LEF substitution was noninferior. https://t.co/F5CGj0w7Bh https://t.co/OuDMgNIKTA
Links:
Dr. John Cush RheumNow ( View Tweet)
For best practices in managing the Delta wave, the US would have done well to consult Puerto Rico
US 26 cases/100,000 people, 19/100K hospitalized 57% vaccinated
PR 3 cases/100,000 people, 3/100K hospitalized, 68% vaccinated https://t.co/kqlXBlmYpu
Eric Topol EricTopol ( View Tweet)
This 15-day-old boy developed this rash, which was diagnosed with neonatal lupus; anti-Ro and anti-La Abs were present, in both, mother and child. The mother never had had symptoms suggesting SLE or any autoimmune disease. The rash healed after 45 days; the boy is doing great😍 https://t.co/fYB0IzE7kY
Emilio Martin Mola emartinmola ( View Tweet)
In case you missed it…a popular read.
Clinical Associations with Myositis Antibodies
Read the full article on #RheumNow
https://t.co/tzPU1scc8x https://t.co/pmmtmIuz31
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast titled Quackademia available for download.
https://t.co/Y6Pqko1tYm https://t.co/Hm22p70d5e
Links:
Dr. John Cush RheumNow ( View Tweet)
Still’s Disease Following COVID-19 Vaccination
https://t.co/23R41Pydve https://t.co/y0loTQuKBH
Links:
Dr. John Cush RheumNow ( View Tweet)
Fluorosis presenting as lower back pain and stiffness of the neck, shoulders, hips, yellowish-brown tooth discoloration, LOM of Cx spine, hips, shoulders. Pelvic Xrays showed osteosclerosis without sacroiliitis. T scores were +12.1 LS spine, alk phos =479 https://t.co/t2lmoudUIM https://t.co/6dWH0Rqhva
Links:
Dr. John Cush RheumNow ( View Tweet)
CXCL13 predicts worse Xray status in early #RA. Study of 158 pts, followed 11-years. Baseline CXCL13 correlated with Xray progression (ΔTSS) at 11 years. CXCL13 was superior to CRP, DAS28CRP, SJC28, CCP predicting 11-yr Xray damage https://t.co/1WAdZoYQ1P
Links:
Dr. John Cush RheumNow ( View Tweet)
Risk of anterior uveitis w/ secukinumab is equal to etanercept; but both inferior to mAb TNFi (infliximab, adalimumab) ~ 5000 Rx starts, AU risk/100PY = SEC 6.8; ETA 7.5; INFLIX 2.9; ADA 4. SEC has a 2.3 fold greater risk than ADA/INFX https://t.co/DB9G2mz4mN
Links:
Dr. John Cush RheumNow ( View Tweet)
Among 2359 RA & PsA pts (3169 TNFi courses 1778/1391), serious infection (SIE) rates were higher in RA 4.17/100PY vs PsA 2.16/100PY. PsA had 41% lower SIE risk (HR 0.59, p=0.004) - Registry data from the NOR-DMARD study https://t.co/llH07TFHOI
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective study hospitalized new-onset systemic JIA (2008-19):52 children’s hospitals & 534 sJiAshows 29% rx w/ biologics & 58% steroids. Over time Biologic use increased & MTX decreased. Biologic correlated w/ Hi hospital volume, ICU stay, later years https://t.co/blbOps9zVQ
Links:
Dr. John Cush RheumNow ( View Tweet)